Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.53 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.48 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19211700 | 1.00 | LMNA (0.64) | LMNAAPOBEC3GALDH1A1SMN1; SMN2HTT | |
| SCHEMBL182738 | 0.97 | LMNA (0.67) | LMNAAPOBEC3GALDH1A1SMN1; SMN2HTT | |
| Water SCHEMBL28154432 | 0.95 | LMNA (0.64) | LMNAAPOBEC3GALDH1A1SMN1; SMN2HTT | |
| SCHEMBL11798300 | 0.93 | LMNA (0.62) | LMNAAPOBEC3GALDH1A1SMN1; SMN2HTT | |
| SCHEMBL23555189 | 0.89 | LMNA (0.63) | LMNAAPOBEC3GALDH1A1SMN1; SMN2HTT | |
| Formic Acid SCHEMBL30498949 | 0.87 | LMNA (0.56) | LMNAAPOBEC3GALDH1A1SMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL28477859 | 0.87 | LMNA (0.61) | LMNAALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL4073854 | 0.84 | LMNA (0.63) | LMNAALDH1A1SMN1; SMN2HTTMAPT | |
| Hydrochloric Acid SCHEMBL29512216 | 0.83 | ALDH1A1 (0.67) | LMNAALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL26413509 | 0.82 | APOBEC3G (0.58) | LMNAAPOBEC3GALDH1A1HSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103224488-A | Heterocyclic compound or salt thereof | OTSUKA PHARMA CO LTD | 2013-07-31 | — | — | CN | claimed |
| CN-101155784-A | Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | claimed |
| CN-101107250-A | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS INC (US) | 2008-01-16 | — | — | CN | claimed |
| EP-1861376-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F. Hoffmann-Roche AG (CH) | 2007-12-05 | — | — | EP | claimed |
| WO-2006097261-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | claimed |
| CN-118339145-A | Bicyclic fused ring derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-07-12 | — | — | CN | disclosed |
| CN-112533897-B | Halogenated allylamine sulfone derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-109153642-B | Indole and azaindole halogenated allylamine derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-109071533-B | Halogenated allylamine indole and azaindole derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| CN-107266332-B | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof | 勃林格殷格翰国际有限公司 | 2020-07-24 | — | — | CN | disclosed |
| CN-110709385-A | Haloallylamine pyrazole derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-7579368-B2 | Cis-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| CN-100497314-C | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA GMBH (DE) | 2009-06-10 | — | — | CN | disclosed |
| CN-101155784-A | Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | disclosed |
| CN-101107250-A | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS INC (US) | 2008-01-16 | — | — | CN | disclosed |
| CN-101056855-A | Nitrogen-containing heterocyclic derivative and drug containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2007-10-17 | — | — | CN | disclosed |
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-06-15 | — | — | US | disclosed |
| CN-1617856-A | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA GMBH (DE) | 2005-05-18 | — | — | CN | disclosed |
| EP-0034432-B1 | SULFAMOYL-SUBSTITUTED PHENETHYLAMINE DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS, CONTAINING THEM | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | HPSE, ENGASE, UGCG | HSD11B1 2202/4885HTR6 4093/4885GAA 215/4885 |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | HAVCR2, MAVS, FABP1 | HSD11B1 3110/4885HTR6 2659/4885GAA 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.